Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9492058rdf:typepubmed:Citationlld:pubmed
pubmed-article:9492058lifeskim:mentionsumls-concept:C1720857lld:lifeskim
pubmed-article:9492058lifeskim:mentionsumls-concept:C0015127lld:lifeskim
pubmed-article:9492058lifeskim:mentionsumls-concept:C0521457lld:lifeskim
pubmed-article:9492058lifeskim:mentionsumls-concept:C0596843lld:lifeskim
pubmed-article:9492058lifeskim:mentionsumls-concept:C0034818lld:lifeskim
pubmed-article:9492058lifeskim:mentionsumls-concept:C1456820lld:lifeskim
pubmed-article:9492058lifeskim:mentionsumls-concept:C1314792lld:lifeskim
pubmed-article:9492058lifeskim:mentionsumls-concept:C0021655lld:lifeskim
pubmed-article:9492058pubmed:issue3lld:pubmed
pubmed-article:9492058pubmed:dateCreated1998-3-12lld:pubmed
pubmed-article:9492058pubmed:abstractTextTreatment of fetal brown adipocytes with 0.6 nM tumor necrosis factor (TNF)-alpha for 24 h resulted in a partial impairment in the expression of fatty acid synthase, glycerol-3-phosphate dehydrogenase, and glucose transporter (GLUT)-4 messenger RNAs (mRNAs), as well as in the enhancement in the cytoplasmic lipid content in response to insulin. However, the expression of the tissue-specific gene, uncoupling protein 1, is increased by the presence of TNF-alpha. The antiadipogenic effect of TNF-alpha was accompanied by a down-regulation of CCAAT/enhancer-binding protein-alpha and beta mRNAs and up-regulation of CCAAT/enhancer-binding protein-delta, with the expression of peroxisome proliferator-activated receptor-gamma remaining essentially unmodified. Moreover, TNF-alpha caused an insulin resistance on the insulin-induced glucose uptake in brown adipocytes. Pretreatment with TNF-alpha resulted in hypophosphorylation of the insulin receptor in response to insulin, without affecting the number of insulin receptors per cell or its molecular mass. However, insulin receptor substrate (IRS)-1 and IRS-2 signaling in response to insulin showed functional differences. Thus, TNF-alpha pretreatment induced a hypophosphorylation of IRS-2 but not of IRS-1. This effect leads to an impairment in the IRS-2-associated phosphatidylinositol (PI) 3-kinase activation due to a decreased association of alpha-p85 regulatory subunit of PI 3-kinase with IRS-2 but not in the IRS-1-associated PI 3-kinase activation in response to insulin. Our results indicate that TNF-alpha induced an IRS-2- but not IRS-1-mediated insulin resistance on glucose transport and lipid synthesis in fetal brown adipocytes.lld:pubmed
pubmed-article:9492058pubmed:languageenglld:pubmed
pubmed-article:9492058pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9492058pubmed:citationSubsetAIMlld:pubmed
pubmed-article:9492058pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9492058pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9492058pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9492058pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9492058pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9492058pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9492058pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9492058pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9492058pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9492058pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9492058pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9492058pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9492058pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9492058pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9492058pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9492058pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9492058pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9492058pubmed:statusMEDLINElld:pubmed
pubmed-article:9492058pubmed:monthMarlld:pubmed
pubmed-article:9492058pubmed:issn0013-7227lld:pubmed
pubmed-article:9492058pubmed:authorpubmed-author:BenitoMMlld:pubmed
pubmed-article:9492058pubmed:authorpubmed-author:LorenziGGlld:pubmed
pubmed-article:9492058pubmed:authorpubmed-author:ValverdeA MAMlld:pubmed
pubmed-article:9492058pubmed:authorpubmed-author:NavarroPPlld:pubmed
pubmed-article:9492058pubmed:authorpubmed-author:TeruelTTlld:pubmed
pubmed-article:9492058pubmed:issnTypePrintlld:pubmed
pubmed-article:9492058pubmed:volume139lld:pubmed
pubmed-article:9492058pubmed:ownerNLMlld:pubmed
pubmed-article:9492058pubmed:authorsCompleteYlld:pubmed
pubmed-article:9492058pubmed:pagination1229-38lld:pubmed
pubmed-article:9492058pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:meshHeadingpubmed-meshheading:9492058-...lld:pubmed
pubmed-article:9492058pubmed:year1998lld:pubmed
pubmed-article:9492058pubmed:articleTitleTumor necrosis factor-alpha causes insulin receptor substrate-2-mediated insulin resistance and inhibits insulin-induced adipogenesis in fetal brown adipocytes.lld:pubmed
pubmed-article:9492058pubmed:affiliationDepartamento de Bioquimica y Biologia Molecular II, Facultad de Farmacia, Universidad Complutense, Madrid, Spain.lld:pubmed
pubmed-article:9492058pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9492058pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9492058lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9492058lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9492058lld:pubmed